Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule belonging to the sulfanilide class of organic compounds. It features a methanesulfonamide group linked to a phenylaniline-pyrimidine scaffold substituted with a 5-chloro-benzodioxole moiety. The drug is listed in chemical and pharmaceutical databases as an experimental agent but does not have an established clinical indication or detailed mechanism of action reported in public sources. Its structure suggests potential kinase inhibitory activity due to the presence of the aminopyrimidine core—a motif common among tyrosine kinase inhibitors—but no specific biological target or pharmacological profile has been confirmed in published literature[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[3-[[4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide.